Intocell Inc
287840
Company Profile
Business description
Intocell Inc possesses independent linker platform technology in the ADC (Antibody-Drug Conjugate) field, which is in the spotlight in the anticancer drug market. The company is researching linker technology that conjugates with drugs and drugs for ADC. The business model of the company is to continuously secure sales through platform technology export that allows linker platform technology to be applied to partner companies' antibodies, and technology export of ADC pipelines.
Contact
101 Sinildong-ro
Daedeok-gu
Daejeon
KORT: +82 427160083
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
These three companies are trading at a significant premium to our fair value.
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.90 | 2.50 | -0.03% |
| CAC 40 | 7,699.16 | 24.38 | 0.32% |
| DAX 40 | 23,760.30 | 163.32 | 0.69% |
| Dow JONES (US) | 45,400.86 | 220.43 | -0.48% |
| FTSE 100 | 9,217.71 | 9.50 | 0.10% |
| HKSE | 25,633.91 | 215.93 | 0.85% |
| NASDAQ | 21,700.39 | 7.30 | -0.03% |
| Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
| NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
| S&P 500 | 6,481.50 | 20.58 | -0.32% |
| S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
| SSE Composite Index | 3,826.84 | 14.33 | 0.38% |